NBIX (Neurocrine Biosciences) FCF Margin % : 9.45% (As of Mar. 2025)

View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Neurocrine Biosciences's Free Cash Flow for the three months ended in Mar. 2025 was $54 Mil. Neurocrine Biosciences's Revenue for the three months ended in Mar. 2025 was $573 Mil. Therefore, Neurocrine Biosciences's FCF Margin % for the quarter that ended in Mar. 2025 was 9.45%.

As of today, Neurocrine Biosciences's current FCF Yield % is 3.86%.

The historical rank and industry rank for Neurocrine Biosciences's FCF Margin % or its related term are showing as below:

NBIX' s FCF Margin % Range Over the Past 10 Years
Min: -735.26 Med: 18.07 Max: 23.66
Current: 20.4

During the past 13 years, the highest FCF Margin % of Neurocrine Biosciences was 23.66%. The lowest was -735.26%. And the median was 18.07%.

NBIX's FCF Margin % is ranked better than
89.76% of 967 companies
in the Drug Manufacturers industry
Industry Median: 0.94 vs NBIX: 20.40

Neurocrine Biosciences FCF Margin % Historical Data

The historical data trend for Neurocrine Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences FCF Margin % Chart

Neurocrine Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

20.81

20.56

21.69

19.16

23.66

Neurocrine Biosciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
FCF Margin %	Get a 7-Day Free Trial															23.11	8.98	24.10	37.47	9.45

Competitive Comparison of Neurocrine Biosciences's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurocrine Biosciences's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Neurocrine Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Neurocrine Biosciences's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	557.2	/	2355.3
	=	23.66 %

Neurocrine Biosciences's FCF Margin for the quarter that ended in Mar. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2025 )	/	Revenue (Q: Mar. 2025 )
	=	54.1	/	572.6
	=	9.45 %

Neurocrine Biosciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (NAS:NBIX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

1NBIX:Italy 0K6R:UK NB3:Germany NB3:Germany N1BI34:Brazil

Address

6027 Edgewood Bend Court, San Diego, CA, USA, 92130

Website

https://www.neurocrine.com

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Executives

Kevin Charles Gorman	officer: Sr VP, Business Development	12790 EL CAMINO REAL, SAN DIEGO CA 92130
William H Rastetter	director	9885 TOWNE CENTRE DR., SAN DIEGO CA 92121
Eiry Roberts	officer: Chief Medical Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Stephen A Sherwin	director	C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080
Ingrid Delaet	officer: Chief Regulatory Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Jude Onyia	officer: Chief Scientific Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
David W. Boyer	officer: Chief Corp. Affairs Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Matt Abernethy	officer: Chief Financial Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92121
Eric Benevich	officer: Chief Commerical Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Kyle Gano	officer: Chief Business Dev Officer	NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Darin Lippoldt	officer: Chief Legal Officer	C/O VOLCANO CORPORATION, 3661 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Julie Cooke	officer: Chief Human Resources Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Gary A Lyons	director, officer: President and CEO	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Shalini Sharp	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Richard F Pops	director	10555 SCIENCE CENTER DR, SAN DIEGO CA 92121